1. 311PEarly results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC). (23rd October 2018) Authors: Shum, M; Assikis, V J; Savulsky, C; Zhu, W; Iyer, P; Xing, D; Berman, C; Lokker, N A; Alvarez, R H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 506PEfficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC). (24th November 2019) Authors: Ward, J P; Shum, M; Bertino, E; Lin, V; Kuruvadi, V; Heineman, T Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗